4//SEC Filing
Campbell David Alan 4
Accession 0001415889-24-027905
CIK 0001817713other
Filed
Nov 26, 7:00 PM ET
Accepted
Nov 27, 8:00 PM ET
Size
7.2 KB
Accession
0001415889-24-027905
Insider Transaction Report
Form 4
Campbell David Alan
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-11-25$52.04/sh−6,719$349,647→ 257,054 total - Sale
Common Stock
2024-11-25$51.43/sh−18,281$940,232→ 263,773 total
Footnotes (3)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.
- [F2]The weighted average sale price for the transaction reported was $51.4322 and the range of prices were between $50.89 and $51.885. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $52.0385 and the range of prices were between $51.89 and $52.385. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Documents
Issuer
Janux Therapeutics, Inc.
CIK 0001817713
Entity typeother
Related Parties
1- filerCIK 0001864158
Filing Metadata
- Form type
- 4
- Filed
- Nov 26, 7:00 PM ET
- Accepted
- Nov 27, 8:00 PM ET
- Size
- 7.2 KB